Payment overview · 2025
General Payments
$463.11
24 reported records · 7 companies
Healthcare provider profile · identity verified
Ashley Caroline Walker, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MIAMI, OK · NPI 1093155111
Verified facts
What the public records show
CMS Open Payments records show Ashley Caroline Walker, D.O. received $463.11 in general payments during 2025 across 24 reported records.
Novo Nordisk Inc accounted for 65.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $301.73 | 65.2% | 15 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.83 | 15.9% | 4 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $21.38 | 4.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $20.86 | 4.5% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.64 | 3.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.20 | 3.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.47 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $463.11 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $195.51 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $195.51 | 8 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $106.22 | 7 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $73.83 | 4 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.43 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $21.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $20.86 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 185 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
185 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 435 | 110 |
| Levothyroxine Sodium | Levothyroxine Sodium | 407 | 97 |
| Gabapentin | Gabapentin | 365 | 101 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 79 |
| Lisinopril | Lisinopril | 276 | 68 |
| Losartan Potassium | Losartan Potassium | 276 | 71 |
| Pantoprazole Sodium | Pantoprazole Sodium | 231 | 66 |
| Furosemide | Furosemide | 189 | 42 |
| Montelukast Sodium | Montelukast Sodium | 189 | 47 |
| Omeprazole | Omeprazole | 185 | 43 |
| Ozempic | Semaglutide | 185 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 156 | 34 |
| Metformin Hcl | Metformin Hcl | 152 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 36 |
| Potassium Chloride | Potassium Chloride | 149 | 41 |
| Carvedilol | Carvedilol | 143 | 39 |
| Meloxicam | Meloxicam | 143 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 37 |
| Trazodone Hcl | Trazodone Hcl | 132 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 131 | 32 |
| Sertraline Hcl | Sertraline Hcl | 131 | 34 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 130 | 54 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 121 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 106 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 105 | 17 |
| Amitriptyline Hcl | Amitriptyline Hcl | 99 | 24 |
| Pregabalin | Pregabalin | 99 | 23 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 27 |
| Buspirone Hcl | Buspirone Hcl | 95 | 23 |
| Eliquis | Apixaban | 92 | 17 |
| Tramadol Hcl | Tramadol Hcl | 91 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 24 |
| Prednisone | Prednisone | 87 | 65 |
| Allopurinol | Allopurinol | 80 | 17 |
| Bupropion Xl | Bupropion Hcl | 80 | 16 |
| Baclofen | Baclofen | 78 | 21 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 74 | 43 |
| Glimepiride | Glimepiride | 73 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 72 | 19 |
| Donepezil Hcl | Donepezil Hcl | 71 | 20 |
| Fluconazole | Fluconazole | 70 | 32 |
| Celecoxib | Celecoxib | 69 | 19 |
| Ondansetron Odt | Ondansetron | 69 | 33 |
| Ezetimibe | Ezetimibe | 67 | 22 |
| Metformin Hcl Er | Metformin Hcl | 67 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 65 | 17 |
| Aripiprazole | Aripiprazole | 62 | 11 |
| Spironolactone | Spironolactone | 61 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 54 | suppressed |
| Simvastatin | Simvastatin | 52 | 13 |
| Clonazepam | Clonazepam | 51 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 30 |
| Methylprednisolone | Methylprednisolone | 51 | 42 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 48 | 36 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 47 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Alprazolam | Alprazolam | 45 | 12 |
| Lorazepam | Lorazepam | 45 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 14 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 44 | 13 |
| Famotidine | Famotidine | 43 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 12 |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 37 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 36 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | 11 |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 35 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 13 |
| Cefdinir | Cefdinir | 34 | 26 |
| Colestipol Hcl | Colestipol Hcl | 34 | suppressed |
| Jardiance | Empagliflozin | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 32 | 13 |
| Nystatin | Nystatin | 32 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | 13 |
| Estradiol | Estradiol | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 14 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 24 |
| Atenolol | Atenolol | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 11 |
| Tamsulosin Hcl | Tamsulosin Hcl | 28 | suppressed |
| Trulicity | Dulaglutide | 27 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 25 | 18 |
| Azithromycin | Azithromycin | 24 | 21 |
| Lovastatin | Lovastatin | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 21 | suppressed |
| Fenofibrate | Fenofibrate | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Belsomra | Suvorexant | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 13 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | 11 |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Sucralfate | Sucralfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $463.11 · 24 records | Novo Nordisk Inc | Auvelity, Dexcom G6 Transmitter, MOUNJARO, NURTEC ODT, Ozempic, QULIPTA, Rybelsus, UBRELVY, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error